Shire Plc: Buy, Sell Or Hold?

What are the long-term prospects for Shire plc (LSE: SHP)?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’m always searching for shares that can help ordinary investors like you make money from the stock market.

Right now I am trawling through the FTSE 100 and giving my verdict on every member of the blue-chip index.

I hope to pinpoint the very best buying opportunities in today’s uncertain market, as well as highlight those shares I feel you should hold… and those I feel you should sell!

I’m assessing every share on five different measures. Here’s what I’m looking for in each company:

1. Financial strength: low levels of debt and other liabilities;

2. Profitability: consistent earnings and high profit margins; 

3. Management: competent executives creating shareholder value;

4. Long-term prospects: a solid competitive position and respectable growth prospects, and;

5. Valuation: an under-rated share price.

A look at Shire

Today I’m evaluating Shire (LSE: SHP), a specialty biopharmaceutical company focusing on rare diseases, which currently trades at 2246p. Here are my thoughts:

1. Financial strength: Shire is in excellent financial health, with a net cash position of £254m and interest cover a hefty 28 times. Also, the company is a cash machine generating around £400m in free cash flow per year during the last 5 years and with a 10-year average free cash flow margin of 20%.

2. Profitability: During the past 10 years, Shire has grown revenue per share and operating profit per share quite consistently by 15% and 18% per year respectively; while adjusted-earnings per share growth has been very variable ranging from around 10% to 140% and a number of years with negative growth. Operating margin has averaged a healthy 19% per year, ranging from the low-teens to mid-twenty percent range and has been expanding the last few of years; while return on invested capital (ROIC) has been stellar at 19% per year over the last 5 years.

3. Management: Angus Russell, the company’s CEO since 2008, has retired after 13 years with the company and has been replaced by Flemming Ornskov, who took the helm on April 30, 2013. Ornskow seems to be a capable replacement — he was the former chief marketing officer at Bayer, a practising physician and has extensive pharmaceutical experience with stints in Novartis, Merck and Bausch & Lomb.

4. Long-term prospects: During the past 18 years, Shire has built itself into a truly global pharmaceutical company through key acquisitions and innovative product development focusing on specialty treatments for rare diseases. The company operates in three main business segments: Specialty Pharmaceuticals, Human Genetic Therapies ((HGT) and Regenerative Medicine. The company’s best selling products include attention-deficit-hyperactivity disorder (ADHD) treatments, where in Shire has 27% share of the US market valued around $8bn and which has delivered more than £1.5bn in revenue in 2012, and HGT medications, which delivered £1.2bn in revenue also in 2012.    

However, sales of the company’s top product Adderall XR — which accounted for 50% of product sales in 2008 — has been dwindling ever since it lost patent protection in 2009. But the company has regained its footing since then. The US ADHD market has grown by an average of 21% per year over the last 3 years — according to IMS, a leading global provider of business intelligence for the pharmaceutical and healthcare market. Also, the company’s other products — Intuniv, an adjunct ADHD treatment for children and adolescents, and HGT treatments Replagal, the market leading treatment for Fabry disease and Vpriv — have shown excellent growth the past few years.

Furthermore, the company has recently gained marketing approval for Elvanse — Shire’s blockbuster ADHD treatment and marketed as Vyvanse in the US — in several countries in Europe earlier this year. This is the first stimulant pro-drug treatment to be launched in Europe for the treatment of ADHD.

On the other hand, the company faces some headwinds in the coming years. Some of the company’s top products will soon deal with generic competition; while performance of the company’s recent acquisitions have been weak.

5. Valuation: The shares look underrated with a price-to-earnings-growth (PEG) ratio of 0.56, a prospective (P/E) of 14, which is below its 10-year P/E average of 16; Also, its trailing price-to-free cash flow ratio (P/FCF) of 16 is well below its 10-year P/FCF average of 24.

My verdict on Shire

Shire has done well with its strategy of focusing on treatments for rare diseases and catering to needs of specialty physicians. It has built a strong portfolio of specialty products and continues to invest in its pipeline. Also, with its huge cash pile, it can continue making acquisitions to boost further growth. Therefore, I think the company can grow around at least high single-digit to double-digit rates for the next few years. Furthermore, its shares looks cheap compared to its historical valuations.

So overall, I believe Shire at 2246p looks like a buy.

More FTSE opportunities

As well as Shire, I am also positive on the FTSE shares highlighted in “8 Dividend Plays Held By Britain’s Super Investor“. This exclusive report reveals the favourite income stocks owned by Neil Woodford — the the City legend whose High Income fund turned £10,000 into £193,000 during the 25 years to 2012.

The report, which explains the full investing logic behind Mr Woodford’s dividend strategy and his preferred blue chips, is free to all private investors. Just click here for your copy. But do hurry, as the report is available for a limited time only.

In the meantime, please stay tuned for my next verdict on a FTSE 100 share.

> Zarr does not own any share mentioned in this article.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Investing Articles

This FTSE 250 stock is up 30% in July! Should I buy it now?

This FTSE 250 technology stock has seen its share price rise by 30% already in July. Roland Head asks if…

Read more »

Investing Articles

Forget Rolls-Royce shares! I’d rather buy this FTSE stock

Despite Rolls-Royce (LSE: RR.) shares faring well in recent times, our writer explains why she would prefer to buy this…

Read more »

Investing Articles

Rio Tinto’s share price slumps following production update! Time to buy in?

Poor production news has pulled Rio Tinto's share price sharply lower again. Is the FTSE 100 mining stock now too…

Read more »

Investing Articles

Could investing £20,000 in a Stocks and Shares ISA make me a millionaire?

Ben McPoland takes a look at how many years it might take to grow a £20k Stocks and Shares ISA…

Read more »

Investing Articles

Are these 2 dividend stocks no-brainer buys for a winning portfolio?

Sumayya Mansoor takes a closer look at these dividend stocks to see if they can help her build wealth through…

Read more »

Investing Articles

Does a 35% price drop make Trufin one of the best AIM shares to buy now?

The Trufin share price has just fallen by over a third after Lloyds terminated a contract. Does this make it…

Read more »

Investing Articles

4% yield and 45% growth in 12 months forecasted! I love this passive income investment

Our author says this passive income investment is significantly undervalued with a generous dividend yield. It's at the top of…

Read more »

Woman sneaker shoe and Arrow on street with copy space background
Investing Articles

£5,000 in savings? Here’s how I’d start investing in FTSE shares today

Based on his own experiences, Paul Summers reflects on the steps he'd take if he wanted to begin investing in…

Read more »